Liquidia Corporation Interest Expense 2011-2026 | LQDA

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Liquidia Corporation

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	-	2.34 M	762 K	858 K	1.37 M	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
2.34 M	762 K	1.33 M

Quarterly Interest Expense Liquidia Corporation

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	3 M	2.6 M	2.52 M	-	1.76 M	1.43 M	1.12 M	-	620 K	542 K	478 K	-	205 K	203 K	150 K	-	191 K	211 K	255 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
3 M	150 K	1.02 M

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
Benitec Biopharma BNTC	-126 K	$ 10.98	-4.52 %	$ 452 M	USA
Ascendis Pharma A/S ASND	80.6 M	$ 221.88	-0.87 %	$ 5 B	Danmark
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
Milestone Pharmaceuticals MIST	2.55 M	$ 1.36	-20.0 %	$ 45.5 M	Canada
Pharming Group N.V. PHAR	10 K	$ 15.36	-0.71 %	$ 7.59 B	Niderland
I-Mab IMAB	722 K	-	-	$ 866 M	China
Genfit SA GNFT	4.68 M	-	2.54 %	$ 160 B	France
Inventiva S.A. IVA	12.2 M	$ 5.78	-4.3 %	$ 138 M	France
Applied Genetic Technologies Corporation AGTC	2.67 M	-	-	$ 26.5 M	USA
ARCA biopharma ABIO	9 K	-	1052.0 %	$ 415 M	USA
AgeX Therapeutics AGE	4.9 M	-	-10.17 %	$ 12.2 K	USA
Acorda Therapeutics ACOR	31.5 M	-	-24.86 %	$ 820 K	USA
Albireo Pharma ALBO	3.69 M	-	-0.23 %	$ 916 M	USA
Aileron Therapeutics ALRN	685 K	-	10.36 %	$ 9.8 M	USA
Assembly Biosciences ASMB	117 K	$ 28.46	3.45 %	$ 319 M	USA
Avenue Therapeutics ATXI	294 K	-	-52.27 %	$ 4.45 M	USA
Autolus Therapeutics plc AUTL	9.29 M	$ 1.37	-4.2 %	$ 350 M	Britain
Adverum Biotechnologies ADVM	8.23 M	-	-	$ 86.2 M	USA
Acer Therapeutics ACER	432 K	-	2.71 %	$ 14 M	USA
Advaxis ADXS	28 K	-	-9.65 %	$ 45.9 M	USA
Axsome Therapeutics AXSM	-15.9 M	$ 156.92	-1.23 %	$ 7.81 B	USA
AbCellera Biologics ABCL	-2.71 M	$ 3.4	-3.68 %	$ 1.02 B	Canada
Atreca BCEL	3 K	-	-11.76 %	$ 5.79 M	USA
BioDelivery Sciences International BDSI	-6 K	-	-4.8 %	$ 255 M	USA
BeiGene, Ltd. BGNE	-42.6 M	-	0.49 %	$ 251 B	Cayman-islands
BioMarin Pharmaceutical BMRN	15.3 M	$ 54.13	-1.64 %	$ 10.4 B	USA
Calithera Biosciences CALA	2.65 M	-	-10.95 %	$ 876 K	USA
Cara Therapeutics CARA	3.59 M	-	-3.03 %	$ 260 M	USA
ChemoCentryx CCXI	2.7 M	-	-	$ 3.74 B	USA
Compugen Ltd. CGEN	281 K	$ 2.09	-0.95 %	$ 195 M	Israel
Coherus BioSciences CHRS	9 M	$ 1.52	-5.59 %	$ 178 M	USA
Checkpoint Therapeutics CKPT	344 K	-	-	$ 169 M	USA
Clovis Oncology CLVS	444 K	-	-7.23 %	$ 13 M	USA
Aeglea BioTherapeutics AGLE	29.5 M	-	-	$ 1.01 B	USA
Corbus Pharmaceuticals Holdings CRBP	1.24 M	$ 8.6	-3.8 %	$ 115 M	USA
Curis CRIS	890 K	$ 0.77	1.89 %	$ 4.86 M	USA
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA